Alixorexton clinical trials
Also written ALKS 2680.
How each study uses alixorexton is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the alixorexton studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ALKS 2680
- 3
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test alixorexton.
- Nov 2026A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaPhase 2 · Alkermes, Inc.
Studies
Open first, then newest update. How each study uses alixorexton is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaRecruitingPhase 2/3Alkermes, Inc.NCT06767683Written as ALKS 2680, 4mg
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaActive, not recruitingPhase 2Alkermes, Inc.NCT06843590Written as ALKS 2680
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)CompletedPhase 2Alkermes, Inc.NCT06358950Written as ALKS 2680
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2CompletedPhase 2Alkermes, Inc.NCT06555783Written as ALKS 2680
Codes
What other systems call alixorexton · ClinicalTrials.gg INT014639
- UNII (FDA) 3BRW4ARU66ALIXOREXTONOne source FDA
- NCI Thesaurus C216006AlixorextonOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3BRW4ARU66 | ALIXOREXTON | One source FDA |
| NCI Thesaurus | C216006 | Alixorexton | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.